

From: [Patel, Amit](#)
To: [Okoye, Christopher](#)
Cc: [Austin-Hansberry, Lori](#)
Subject: [EXTERNAL] RE: FDA Waiver - COMIRNATY
Date: Wednesday, September 29, 2021 5:04:08 PM
Attachments: [image001.png](#)

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Christopher, I confirm receipt.

Thanks
Amit

From: Okoye, Christopher <Christopher.Okoye@fda.hhs.gov>
Sent: Wednesday, September 29, 2021 3:58 PM
To: Patel, Amit <Amitkumar.Patel@pfizer.com>
Cc: Austin-Hansberry, Lori <Lori.Austin-Hansberry@fda.hhs.gov>
Subject: [EXTERNAL] FDA Waiver - COMIRNATY

Dear Amit Patel:

Attached is the FDA Waiver Response Letter for COMIRNATY, STN 125742/0.

This letter is the official copy for your records. This email will not be followed with a paper copy.

Please confirm receipt of this message.

Thank you,

Christopher Okoye, PharmD Christopher C. Okoye -S
LT, U.S. Public Health Service
Regulatory Project Manager, Division of Epidemiology

Digitally signed by Christopher C. Okoye -S
DN: c=US, o=U.S. Government, ou=HHS,
ou=FDA, ou=People,
0.9.2342.19200300.100.1.1+2002477380,
cn=Christopher C. Okoye -S
Date: 2021.10.01 00:16:34 -0400

Center for Biologics Evaluation and Research
Office of Biostatistics and Epidemiology
U.S. Food and Drug Administration
Tel: (240) 402-6996
Christopher.Okoye@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY

CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.